AstraZeneca Suffers U.S. Patent Loss for Childhood Asthma Drug

Generic Line
A A
A U.S. patent protecting AstraZeneca’s (AZ) Pulmicort Respules was deemed invalid last week, opening the door for generic versions of the asthma drug to hit store shelves.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00